Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients

International Journal of Hematology

Volumn 95, Issue 1, 2012, Pages 64-70

  Kaya, Hakan ^a   Peressini, Benjamin ^b   Jawed, Irfan ^a   Martincic, Danko ^a   Elaimy, Ameer L ^a   Lamoreaux, Wayne T ^a   Fairbanks, Robert K ^a   Weeks, Kevin A ^a   Lee, Christopher M ^a  

^a Cancer Care Northwest   (United States)

^b DataWorks Northwest   (United States)

Author keywords

Asian Pacific Islander; Multiple myeloma; Overall survival; Population analysis; Race; SEER

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; RACE; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; INUITS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OCEANIC ANCESTRY GROUP; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84857637995     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0971-z     Document Type: Conference Paper

References (36)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. D Rades G Bohlen A Pluemer T Veninga P Hanssens J Dunst, et al. 2007 Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients Cancer. 109 2515 2521 17487853 10.1002/cncr.22729 (Pubitemid 46906471)
3. N Blokhin L Larionov N Perevodchikova L Chebotareva N Merkulova 1958 Clinical experiences with sarcolysin in neoplastic diseases Ann N Y Acad Sci 68 1128 1132 13627766 10.1111/j.1749-6632.1958.tb42675.x 1:STN:280: DyaG1M%2FlsleitQ%3D%3D
4. SE Salmon RK Shadduck A Schilling 1967 Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma Cancer Chemother Rep. 51 179 187 6043738 1:STN:280:DyaF2s3ls1aisw%3D%3D
5. OR McIntyre TF Pajak RA Kyle GG Cornwell 3rd L Leone 1985 Response rate and survival in myeloma patients receiving prednisone alone Med Pediatr Oncol 13 239 243 4033539 10.1002/mpo.2950130502 1:STN:280:DyaL2M3psFOjsg%3D%3D (Pubitemid 15227884)
6. M Attal JL Harousseau AM Stoppa JJ Sotto JG Fuzibet JF Rossi, et al. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med. 335 91 97 8649495 10.1056/NEJM199607113350204 1:STN:280:DyaK283ms1emuw%3D%3D (Pubitemid 26240110)
7. J Labardini-Mendez R Alexanian B Barlogie 1997 Multiple myeloma and chronic lymphocytic leukemia Rev Invest Clin 49 Suppl 1 28 33 9380986
8. S Singhal J Mehta R Desikan D Ayers P Roberson P Eddlemon, et al. 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565 1571 10564685 10.1056/NEJM199911183412102 1:CAS:528:DyaK1MXotVSgs78%3D
9. PG Richardson B Barlogie J Berenson S Singhal S Jagannath D Irwin, et al. 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 2617 12826635 10.1056/NEJMoa030288 1:CAS:528:DC%2BD3sXkvVSksLs%3D (Pubitemid 36741588)
10. M Dimopoulos A Spencer M Attal HM Prince JL Harousseau A Dmoszynska, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123 2132 18032762 10.1056/NEJMoa070594 1:CAS:528:DC%2BD2sXhtlGis7nN (Pubitemid 350146107)
11. DM Weber C Chen R Niesvizky M Wang A Belch EA Stadtmauer, et al. 2007 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133 2142 18032763 10.1056/NEJMoa070596 1:CAS:528: DC%2BD2sXhtlGis7bM (Pubitemid 350146108)
12. SK Kumar SV Rajkumar A Dispenzieri MQ Lacy SR Hayman FK Buadi, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520 17975015 10.1182/blood-2007-10-116129 1:CAS:528: DC%2BD1cXivFaktrk%3D
13. F van Rhee M Dhodapkar JD Shaughnessy Jr E Anaissie D Siegel A Hoering, et al. 2008 First thalidomide clinical trial in multiple myeloma: a decade Blood 112 1035 1038 18502827 10.1182/blood-2008-02-140954
14. H Brenner A Gondos D Pulte 2008 Recent major improvement in long-term survival of younger patients with multiple myeloma Blood 111 2521 2526 17901246 10.1182/blood-2007-08-104984 1:CAS:528:DC%2BD1cXivFaktrY%3D
15. E Kastritis K Zervas A Symeonidis E Terpos S Delimbassi N Anagnostopoulos, et al. 2009 Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) Leukemia. 23 1152 1157 19225533 10.1038/leu.2008.402 1:CAS:528:DC%2BD1MXntFygtLw%3D
16. JF San Miguel R Schlag NK Khuageva MA Dimopoulos O Shpilberg M Kropff, et al. 2008 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 906 917 18753647 10.1056/NEJMoa0801479 1:CAS:528:DC%2BD1cXhtVGms77K
17. H Brenner A Gondos D Pulte 2009 Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010 Haematologica. 94 270 275 19144659 10.3324/haematol.13782
18. SY Kristinsson O Landgren PW Dickman AR Derolf M Bjorkholm 2007 Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003 J Clin Oncol 25 1993 1999 17420512 10.1200/JCO.2006.09.0100 (Pubitemid 46972782)
19. H Goldschmidt U Hegenbart M Wallmeier M Moos R Haas 1997 High-dose chemotherapy in multiple myeloma Leukemia 11 Suppl 5 S27 S31 9436935 1:CAS:528:DyaK1cXos1Kqtg%3D%3D
20. R Alexanian M Dimopoulos 1994 The treatment of multiple myeloma N Engl J Med 330 484 489 8289856 10.1056/NEJM199402173300709 1:STN:280: DyaK2c7hvFWntA%3D%3D
21. JR Berenson L Rajdev M Broder 2006 Bone complications in multiple myeloma Cancer Biol Ther 5 1082 1085 16969119 10.4161/cbt.5.9.3307 (Pubitemid 44772215)
22. F Saad A Lipton R Cook YM Chen M Smith R Coleman 2007 Pathologic fractures correlate with reduced survival in patients with malignant bone disease Cancer. 110 1860 1867 17763372 10.1002/cncr.22991 (Pubitemid 47557312)
23. SR Alberts AP Lanier 1987 Leukemia, lymphoma, and multiple myeloma in Alaskan natives J Natl Cancer Inst 78 831 837 3471994 1:STN:280: DyaL2s7pvFGrug%3D%3D (Pubitemid 17093006)
24. J Swan BK Edwards 2003 Cancer rates among American Indians and Alaska Natives: is there a national perspective Cancer. 98 1262 1272 12973851 10.1002/cncr.11633 (Pubitemid 37099912)
25. M Benjamin S Reddy OW Brawley 2003 Myeloma and race: a review of the literature Cancer Metastasis Rev 22 87 93 12716040 10.1023/A:1022268103136 1:CAS:528:DC%2BD3sXpt1Wkuw%3D%3D (Pubitemid 36363517)
26. AJ Waxman PJ Mink SS Devesa WF Anderson BM Weiss SY Kristinsson, et al. 2010 Racial disparities in incidence and outcome in multiple myeloma: a population-based study Blood 116 5501 5506 20823456 10.1182/blood-2010-07-298760 1:CAS:528:DC%2BC3MXhtFGkur8%3D
27. SV Rajkumar E Blood D Vesole R Fonseca PR Greipp 2006 Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 431 436 16365178 10.1200/JCO.2005.03. 0221 1:CAS:528:DC%2BD28XhsFSku7s%3D (Pubitemid 46630462)
28. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112(12):4445-51.
29. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA Trial. J Clin Oncol. 2010;28(13):2259-66.
30. DJ Kuhn Q Chen PM Voorhees JS Strader KD Shenk CM Sun, et al. 2007 Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 110 3281 3290 17591945 10.1182/blood-2007-01-065888 1:CAS:528: DC%2BD2sXht1yqur3L (Pubitemid 350106321)
31. MQ Lacy SR Hayman MA Gertz A Dispenzieri F Buadi S Kumar, et al. 2009 Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma J Clin Oncol 27 5008 5014 19720894 10.1200/JCO.2009.23.6802 1:CAS:528:DC%2BD1MXhsVCrsrzE
32. E David R Sinha J Chen SY Sun JL Kaufman S Lonial 2008 Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors Clin Cancer Res 14 5090 5098 18698026 10.1158/1078-0432.CCR- 08-0016 1:CAS:528:DC%2BD1cXpslKgtL4%3D
33. C Erlichman 2009 Tanespimycin: the opportunities and challenges of targeting heat shock protein 90 Expert Opin Investig Drugs 18 861 868 19466875 10.1517/13543780902953699 1:CAS:528:DC%2BD1MXmtlWqsbo%3D
34. C Fionda A Soriani G Malgarini ML Iannitto A Santoni M Cippitelli 2009 Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation J Immunol 183 4385 4394 19748980 10.4049/jimmunol.0901797 1:CAS:528:DC%2BD1MXhtFGjs7fI
35. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49(3):502-7. (Pubitemid 351298334)
36. Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández- Lázaro D, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010;95(5):794-803.